# Sanofi Pasteur, a Sanofi Company clinical trials: 374 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 374 trials with Sanofi Pasteur, a Sanofi Company as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sanofi Pasteur, a Sanofi Company: 374 rows for $18.70, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sanofi-pasteur-a-sanofi-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 374
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 374, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 17, 2026 | NCT07536048 | A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years | Sanofi Pasteur, a Sanofi Company | Observational | Active not recruiting | Epstein-Barr Virus (EBV), Healthy Volunteers | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07536048) |
| October 29, 2025 | NCT07222059 | Phase 3 Single Arm, Open Study on vYF in Adults | Sanofi Pasteur, a Sanofi Company | Phase 3 | Completed | Yellow Fever | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222059) |
| June 10, 2025 | NCT07013747 | Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne | Sanofi Pasteur, a Sanofi Company | Phase 1/2 | Recruiting | Acne | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07013747) |
| February 20, 2025 | NCT06838000 | Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants... | Sanofi Pasteur, a Sanofi Company | Phase 3 | Active not recruiting | Pneumococcal Infections | 1,268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06838000) |
| February 13, 2025 | NCT06824207 | Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants | Sanofi Pasteur, a Sanofi Company | Observational | Completed | Respiratory Syncytial Virus Immunization | 2,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06824207) |
| January 30, 2025 | NCT06800885 | Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants | Sanofi Pasteur, a Sanofi Company | Observational | Completed | Influenza Immunization | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06800885) |
| January 27, 2025 | NCT06793826 | Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea | Sanofi Pasteur, a Sanofi Company | Observational | Completed | Hepatitis B, Haemophilus Influenzae Type b Immunisation | 713 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793826) |
| December 20, 2024 | NCT06744205 | A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older | Sanofi Pasteur, a Sanofi Company | Phase 1/2 | Completed | Influenza, Healthy Volunteers | 1,162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06744205) |
| December 16, 2024 | NCT06736041 | Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Sanofi Pasteur, a Sanofi Company | Phase 3 | Active not recruiting | Pneumococcal Immunization | 1,714 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736041) |
| December 10, 2024 | NCT06727058 | Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | Sanofi Pasteur, a Sanofi Company | Phase 1/2 | Completed | Influenza Immunization | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06727058) |
| November 26, 2024 | NCT06705140 | A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers | Sanofi Pasteur, a Sanofi Company | Phase 3 | Terminated | RSV Immunisation, Healthy Volunteers | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06705140) |
| November 20, 2024 | NCT06698198 | Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years) | Sanofi Pasteur, a Sanofi Company | Phase 1 | Completed | Pneumococcal Immunization | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06698198) |
| November 13, 2024 | NCT06686654 | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation... | Sanofi Pasteur, a Sanofi Company | Phase 1/2 | Active not recruiting | Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization | 1,530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06686654) |
| October 17, 2024 | NCT06647407 | Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children... | Sanofi Pasteur, a Sanofi Company | Phase 1/2 | Active not recruiting | Meningococcal Immunization, Healthy Volunteers | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06647407) |
| October 15, 2024 | NCT06641180 | Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age | Sanofi Pasteur, a Sanofi Company | Phase 3 | Completed | Influenza | 1,180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06641180) |
| September 19, 2024 | NCT06604767 | Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older | Sanofi Pasteur, a Sanofi Company | Phase 1 | Completed | Respiratory Syncytial Virus Infection, Metapneumovirus Infection, Parainfluenzae Virus Infection | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06604767) |
| September 3, 2024 | NCT06583031 | Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and... | Sanofi Pasteur, a Sanofi Company | Phase 1 | Completed | RSV Infection, hMPV | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06583031) |
| September 3, 2024 | NCT06582056 | Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age | Sanofi Pasteur, a Sanofi Company | Not applicable | Completed | Periodontal Disease | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06582056) |
| July 18, 2024 | NCT06507553 | Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and... | Sanofi Pasteur, a Sanofi Company | Phase 1 | Completed | Influenza, Healthy Volunteers | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06507553) |
| May 3, 2024 | NCT06397768 | Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers | Sanofi Pasteur, a Sanofi Company | Phase 3 | Terminated | RSV Immunization | 2,226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06397768) |
| April 12, 2024 | NCT06361875 | A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above | Sanofi Pasteur, a Sanofi Company | Phase 1/2 | Completed | Influenza Immunization, Healthy Volunteers | 908 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06361875) |
| March 22, 2024 | NCT06325332 | BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) | Sanofi Pasteur, a Sanofi Company | Observational | Completed | Respiratory Syncytial Virus | 49,680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06325332) |
| March 18, 2024 | NCT06316297 | Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne | Sanofi Pasteur, a Sanofi Company | Phase 1/2 | Recruiting | Acne | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06316297) |
| February 29, 2024 | NCT06284915 | Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers | Sanofi Pasteur, a Sanofi Company | Phase 3 | Completed | Meningococcal Immunisation, Healthy Volunteers | 840 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06284915) |
| February 9, 2024 | NCT06252285 | Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers | Sanofi Pasteur, a Sanofi Company | Phase 3 | Terminated | RSV Immunisation | 6,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06252285) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 25 |
| Phase 1/2 | 24 |
| Phase 2 | 80 |
| Phase 2/3 | 1 |
| Phase 3 | 141 |
| Phase 4 | 62 |
| Not applicable | 2 |
| Observational | 39 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 344 |
| Terminated | 16 |
| Active not recruiting | 9 |
| Recruiting | 4 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 116 |
| Diphtheria | 58 |
| Whooping Cough | 58 |
| Tetanus | 56 |
| Meningococcal Infections | 53 |
| Poliomyelitis | 42 |
| Meningitis | 40 |
| Dengue | 30 |
| Hepatitis B | 28 |
| Haemophilus Infections | 26 |
| Severe Dengue | 25 |
| Meningitis, Meningococcal | 22 |
| Orthomyxoviridae Infections | 20 |
| Encephalitis, Japanese | 11 |
| Rabies | 11 |
| Respiratory Syncytial Virus Infections | 9 |
| Yellow Fever | 7 |
| Hepatitis A | 6 |
| Measles | 6 |
| Mumps | 5 |
| Rubella | 5 |
| Chickenpox | 5 |
| Smallpox | 5 |
| COVID-19 | 4 |
| Clostridium Infections | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Mental health clinics in the United States](https://specstream.ai/data/businesses/mental-health-clinics/united-states)
- [Computer training centers in the United States](https://specstream.ai/data/businesses/computer-training-centers/united-states)
- [Spring suppliers in the United States](https://specstream.ai/data/businesses/spring-suppliers/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
